Literature DB >> 17073518

Atypical cytochrome p450 kinetics: implications for drug discovery.

Timothy S Tracy1.   

Abstract

The Michaelis-Menten model is commonly used to estimate a drug's potential in vivo hepatic clearance based on in vitro data obtained during drug discovery and development. This paradigm assumes that the drug obeys 'typical' enzyme kinetics and thus can be described by this model. However, it is increasingly being recognised that a number of drugs metabolised not only by the cytochrome P450 enzymes but also by other enzymes and transporters can exhibit atypical kinetic profiles, and thus are not accurately modeled with the Michaelis-Menten model. Application of an incorrect model can then lead to mis-estimation of in vitro intrinsic clearance and thus affect the prediction of in vivo clearance. This review discusses several types of atypical kinetic profiles that may be observed, including examples of homotropic cooperativity (i.e. sigmoidal kinetics, biphasic kinetics and substrate inhibition kinetics) as well as heterotropic cooperativity (i.e. activation). Application of the incorrect kinetic model may profoundly affect estimations of intrinsic clearance. For example, incorrectly applying the Michaelis-Menten model to a kinetic profile exhibiting substrate inhibition kinetics will result in an underestimation of Km (Michaelis-Menten constant) and V(max) (maximal velocity), whereas application of the Michaelis-Menten model to sigmoidal kinetic data typically results in an overestimation of Km and V(max) at the lower substrate concentrations that are typically therapeutically relevant. One must also be careful of potential artefactual causes of atypical kinetic profiles, such as enzyme activation by solvents, buffer dependent kinetic profiles, or altered kinetic parameter estimates due to nonspecific binding of the substrate to proteins. Despite a plethora of data on the effects of atypical kinetic profiles in vitro, only modest effects have been noted in vivo (with the exception of substrate dependent inhibition). Thus, the clinical relevance of these phenomena remains inconclusive.

Mesh:

Substances:

Year:  2006        PMID: 17073518     DOI: 10.2165/00126839-200607060-00004

Source DB:  PubMed          Journal:  Drugs R D        ISSN: 1174-5886


  17 in total

Review 1.  Substrate binding to cytochromes P450.

Authors:  Emre M Isin; F Peter Guengerich
Journal:  Anal Bioanal Chem       Date:  2008-07-13       Impact factor: 4.142

2.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

Review 3.  A novel type of allosteric regulation: functional cooperativity in monomeric proteins.

Authors:  Ilia G Denisov; Stephen G Sligar
Journal:  Arch Biochem Biophys       Date:  2012-01-08       Impact factor: 4.013

4.  Numerical Methods for Modeling Enzyme Kinetics.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Methods Mol Biol       Date:  2021

5.  Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2019-05-01       Impact factor: 3.922

6.  Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis.

Authors:  Haoming Zhang; Sean C Gay; Manish Shah; Maryam Foroozesh; Jiawang Liu; Yoichi Osawa; Qinghai Zhang; C David Stout; James R Halpert; Paul F Hollenberg
Journal:  Biochemistry       Date:  2013-01-04       Impact factor: 3.162

7.  Effects of some commonly used Saudi folk herbal medications on the metabolic activity of CYP2C9 in human liver microsomes.

Authors:  Fahad I Al-Jenoobi
Journal:  Saudi Pharm J       Date:  2010-05-31       Impact factor: 4.330

Review 8.  Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation.

Authors:  Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-02       Impact factor: 4.481

9.  Dioxygenases catalyze O-demethylation and O,O-demethylenation with widespread roles in benzylisoquinoline alkaloid metabolism in opium poppy.

Authors:  Scott C Farrow; Peter J Facchini
Journal:  J Biol Chem       Date:  2013-08-08       Impact factor: 5.157

10.  Cooperativity of cytochrome P450 1A2: interactions of 1,4-phenylene diisocyanide and 1-isopropoxy-4-nitrobenzene.

Authors:  Emre M Isin; Christal D Sohl; Robert L Eoff; F Peter Guengerich
Journal:  Arch Biochem Biophys       Date:  2008-02-29       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.